Insulin resistance — the foundation
Insulin is the hormone that moves glucose from the bloodstream into cells. In insulin resistance, cells respond less effectively and the pancreas compensates by producing more insulin. Over years, this compensation fails and blood glucose rises into the prediabetes and type 2 diabetes range. Insulin resistance is influenced by genetics, excess adipose tissue, ectopic fat in the liver and pancreas, low physical activity, sleep, and chronic inflammation.
Metabolic disease is more than blood sugar
Metabolic disease is a cluster of related conditions: type 2 diabetes, hypertension, dyslipidemia, MASLD/NAFLD (fatty liver), obstructive sleep apnea, and cardiovascular risk. They share underlying biology, so an intervention that improves one often improves the others.
Weight regulation is a hormone system, not willpower
Body weight is regulated by hormones from the gut (GLP-1, GIP, PYY, ghrelin, CCK), adipose tissue (leptin), and the brain. When the body loses weight, these hormones change to defend the previous weight — which is why diet alone rarely produces durable change. Modern treatments — both pharmacological and surgical — work by influencing this hormone system.
What metabolic surgery actually changes
- Gut hormone signaling — rerouting or altering food contact with the small intestine changes GLP-1, GIP, PYY, and ghrelin release.
- Bile acid pathways — bile acid signaling through FXR and TGR5 receptors influences glucose and energy metabolism.
- Microbiome composition — changes in gut bacteria after surgery affect metabolism.
- Stomach volume and emptying — restricting volume and changing how quickly food reaches the small intestine.
- Neural feedback — vagal signaling between gut and brain is modified.
The MagDI™ magnetic approach
The MagDI™ device uses two magnets to create a duodeno-ileal anastomosis — a connection between the duodenum and the ileum — that bypasses a segment of the small intestine. The FDA has authorized MagDI™ for the creation of this anastomosis. FDA authorization for the device does not represent FDA approval for diabetes remission, weight loss, or any specific clinical outcome. Outcomes vary; no result is guaranteed.
Other established procedures
- Sleeve gastrectomy — reduces stomach volume and lowers ghrelin.
- Roux-en-Y gastric bypass — combines a small gastric pouch with intestinal rerouting.
- SADI-S / duodenal switch — combines sleeve with intestinal bypass.
Each procedure has different risk and benefit profiles. Choice depends on individual factors and is determined by the surgical team.
What surgery cannot do
- It cannot eliminate the genetic tendency toward insulin resistance.
- It cannot replace long-term nutrition, activity, and follow-up.
- It cannot guarantee diabetes remission.
- It is not appropriate for every patient.
The role of comprehensive care
Surgery is one component of a comprehensive metabolic care plan that includes preoperative optimization, structured nutrition, supervised activity, mental health support, and lifelong follow-up. The strength of a program is in the integration of these elements.
Sources
- Cummings DE, Rubino F. Metabolic surgery for the treatment of type 2 diabetes. Diabetologia, 2018.
- Schauer PR et al. STAMPEDE trial — 5-year outcomes. NEJM, 2017.
- ASMBS/IFSO 2022 Indications for Metabolic and Bariatric Surgery.
- NIH/NIDDK. Bariatric Surgery: Procedures.
Ready for an individualized evaluation?
A physician evaluation is the only way to determine candidacy. Outcomes vary; no result is guaranteed.